Fundraiser hosted by University of Windsor students looks to raise as much money as possible in one hour
Windsor, Ont. — A fundraiser hosted by University of Windsor students from the school's Medlife chapter hopes to show how much heart the city really has.
Due to COVID-19, the organization which partners with low-income communities in Latin America and Africa to improve access to medicine, education and community development initiatives is unable to be on the ground in these areas and is instead holding its Moving Mountains Fundraiser.
'Due to the COVID-19 Pandemic, we have been unable to go on a service learning trip, and our organization has been working on ways to support underprivileged communities in South America,' University of Windsor's Medlife chapter co-presidents Mohammed Abdulaziz and Saya Albonaimi said in an email to CTV Windsor.
There are more than 264 Medlife chapters across North America, in addition to service trips, the organization has a Medlife Project Fund which aims to raise money to send to impoverished communities around the world.
'Our current initiative is the Moving Mountains Fundraiser, where over 100 plus Universities across North America have participated in raising money for food, water, and supplies to communities that simply do not have the privileges we are so blessed to have,' Abdulaziz said.
The fundraiser will be held on July 17, from 7 p.m. to 8 p.m. where UWindsor students will be contacting people to try and raise as much money by contacting as many people as they can to raise as much money as possible in an hour.
So far, the best performing University in North America is Queens who raised almost $9,500 in one hour to send to vulnerable families impacted by COVID-19 raising $9,500 in one hour.
'Our Windsor chapter is looking to show that our smaller community has more heart and spirit than our size suggests, and we are going to put our best foot forward for our fundraiser on July 17, 7 p.m. – 8 p.m., having a friendly competition with UOttawa and McMaster University to see who can raise the most money,' Abdulaziz said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
44 minutes ago
- National Post
Market to Grow by 12.1% to Reach $6.97 Billion this Year - Investment Opportunities to 2029
Article content DUBLIN — The 'Canada Diabetes Devices and Therapeutics Market Investment Opportunities – Q2 2025 Update' report has been added to offering. Article content The diabetes market in Canada is expected to grow by 12.1% on annual basis to reach US$6.97 billion in 2025. The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 12.9%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 10.0% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 6.22 billion to approximately USD 11.37 billion. Article content This report provides a detailed data-centric analysis of the diabetes industry in Canada, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics. Article content The diabetes devices and therapeutics market in Canada comprises established multinational firms and emerging domestic players. A structured healthcare system with defined reimbursement pathways supports traditional and digital solutions. The Canadian diabetes devices and therapeutics market is characterized by a blend of multinational leaders and emerging technology-driven entrants. Recent strategic partnerships, mergers, and acquisitions indicate a move toward more integrated care solutions. In the coming years, competitive dynamics are expected to intensify, driven by consolidation and a focused shift toward digital integration and regulatory compliance. Article content The Canadian market is experiencing significant shifts, with increased CGM adoption, digital integration, advanced therapeutic systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures across provincial healthcare systems. Article content Expand Continuous Glucose Monitoring Usage Article content Canadian healthcare systems are broadening the use of continuous glucose monitoring (CGM) devices across several provinces. Provincial pilot programs in regions such as Ontario and British Columbia are incorporating CGM into routine diabetes care. Adjustments in provincial reimbursement policies and recent clinical studies from Canadian health agencies support wider CGM use. Recent publications have highlighted a shift in clinical practice toward data-driven patient monitoring. The adoption of CGM is expected to intensify as more provinces expand coverage and integrate real-time data into care protocols. Enhanced patient monitoring may improve diabetes management outcomes over the medium term. Article content Digital health platforms that support remote monitoring and telemedicine are increasingly integrated into diabetes management in Canada. Several regional healthcare systems have initiated digital dashboards to consolidate patient data for clinical decision-making. Government initiatives to improve telehealth services and recent shifts in healthcare delivery models are driving digital integration. Recent publications underscore provincial health ministries' investments in digital infrastructure. The integration of digital tools is projected to grow, supporting real-time care adjustments and enhanced data sharing among providers. This trend is expected to intensify as digital health reshapes chronic disease management. Article content Advance Therapeutic Delivery Systems Article content Advanced therapeutic devices such as smart insulin pens and connected insulin pumps are being tested in clinical settings across Canada. Pilot programs in select provinces have assessed these devices for precise dosing and improved treatment adherence. Recent technological improvements and research findings from Canadian institutions support the development of these systems. Funding and innovation incentives from provincial health programs are fostering the introduction of these therapeutic tools. Adoption will likely grow as clinical evidence and reimbursement models evolve, integrating these devices into standard practice. The trend is expected to intensify gradually, influencing treatment protocols in diabetes care. Article content Regulatory and Reimbursement Models Article content Regulatory bodies in Canada are updating guidelines and reimbursement policies to accommodate new diabetes devices and therapeutics. Recent policy documents have outlined pathways for including digital health and connected devices in public healthcare programs. Broader cost-containment strategies and ongoing evaluations of digital health effectiveness drive regulatory adjustments. Publications from provincial health ministries and Health Canada provide context for these evolving frameworks. Clearer regulatory and reimbursement models are anticipated to further support device integration and market expansion. These changes are expected to have a progressive impact, offering more defined channels for innovation in diabetes management. Article content Key Competitors and New Entrants Article content Several longstanding multinational companies hold significant market share. They offer a range of devices, from continuous monitoring systems to therapeutic delivery tools, and maintain strategic relationships with provincial healthcare agencies. New market entrants, including technology-focused startups, are introducing digital health solutions that target remote monitoring and data integration. Recent publications indicate that pilot programs in provinces allow these entrants to demonstrate value. Article content Recent publications detail partnerships where established companies collaborate with digital health startups to enhance device connectivity and patient data analytics. Mergers and acquisitions have been noted as firms consolidate technical expertise and broaden their market offerings within the Canadian context. These strategic developments reshape the market by promoting integrated care solutions and streamlined regulatory compliance. Collaborative efforts are aligning product innovation with provincial healthcare priorities. Article content Future Competitive Dynamics (2-4 Years) Article content The competitive landscape is expected to evolve as strategic partnerships and consolidation efforts deepen. Companies will likely increase investments in digital health integration, balancing established market leaders with nimble entrants. Over the next 2-4 years, market consolidation and technology-driven innovation are anticipated to further define competitive positioning, with clear implications for patient management strategies. Article content Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Article content Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Article content Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Article content Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Article content Insulin Pumps Insulin Pens Insulin Syringes Article content Diabetes Devices and Therapeutics Market Share by Therapeutics Article content Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Article content Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Article content Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Article content Diabetes Devices and Therapeutics Market Share by Insulin Article content Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Article content Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs Article content GLP-1 Receptor Agonists Amylin Analogue Article content Diabetes Devices and Therapeutics Market Share by Combination Drugs Article content Combination Insulin Oral Combination Article content Diabetes Devices and Therapeutics Market Share by Route of Administration Article content Subcutaneous Intravenous Others Article content Diabetes Devices and Therapeutics Market Share by Type of Diabetes Article content Type 1 Diabetes Type 2 Diabetes Article content Diabetes Devices and Therapeutics Market Share by Distribution Channels Article content Online Pharmacies Hospital Pharmacies Retail Pharmacies Article content Diabetes Devices and Therapeutics Market Share by End User Article content Hospitals Diabetes Clinics Homecare Article content Key Attributes: Article content Report Attribute Details No. of Pages 50 Forecast Period 2025 – 2029 Estimated Market Value (USD) in 2025 $7.77 Billion Forecasted Market Value (USD) by 2029 $11.37 Billion Compound Annual Growth Rate 10.0% Regions Covered Canada Article content For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Article content Article content Article content Article content Article content Contacts Article content Article content
CTV News
an hour ago
- CTV News
More salami recalled amid Salmonella outbreak
Rea's sweet soppressata salami joins the latest recalls linked to an outbreak of Salmonella infections. (Handout) The Canadian Food Inspection Agency (CFIA) has issued a recall for Rea's sweet soppressata salami due to possible salmonella contamination. The affected product is identified by its Universal Product Code 841571 042200. Consumers are urged to check for affected products and dispose of or return any items matching the listed UPC immediately. The latest recall comes on the heels of a salmonella outbreak tied to pork deli meats sold at grocery stores and in prepared sandwiches. The Public Health Agency of Canada (PHAC) said the infections are linked to Rea brand Genoa Salami Sweet, Rea brand Genoa Salami Hot and Bona brand Mild Genova Salam - which was recalled by the CFIA on June 10 in three provinces. Since April, 84 people have gotten sick and there have now been nine hospitalizations, according to the PHAC. As of July 11, 67 people are sickened in Alberta, 15 people in Ontario and one person in Manitoba. One illness reported in B.C. is related to travel to Alberta. What is Salmonella? Salmonella is a food-borne bacterial illness that can spread several days or weeks after a person is infected, even if they don't have symptoms. According to the CFIA, healthy people may experience short-term symptoms such as fever, headache, vomiting, nausea, abdominal cramps and diarrhea. Severe arthritis is a possibility in long-term complications, it added. Salmonella-contaminated food may not look or smell spoiled but can still cause illness, it warned. The CFIA says most people who become ill from a salmonella infection can recover fully after a few days without treatment, while in other cases it can cause severe illness and hospitalization. What you should do Consumers are urged to check product labels and UPC codes against CFIA's alerts. The health agency also advises consumers to not consume any recalled items or food containing them and discard or return affected items to the place of purchase.
CTV News
an hour ago
- CTV News
‘We're going to continue to fight:' B.C. ostrich farm to fight case to cull its herd in Federal Court of Appeal
A sign calling for the protection of ostriches at the Universal Ostrich Farms is displayed in Edgewood, B.C., on Saturday, May 17, 2025. Hundreds of supporters flocked to the farm over the Victoria Day long weekend to protest the Canadian Food Inspection Agency's order to cull about 400 ostriches. THE CANADIAN PRESS/Aaron Hemens A B.C. ostrich farm that lost dozens of birds following an avian flu outbreak last winter will be fighting in the Federal Court of Appeal in Ottawa on Tuesday to stop an order to cull the remainder of its herd. Today's hearing marks the latest development in a legal battle by Universal Ostrich Farm, located near Edgewood, B.C., to save its birds. 'We're going to continue to fight with all that we have,' Katie Pasitney, the daughter of the farm owners, said in an interview with CTV News before the hearing. 'It is very real that if we are not guaranteed Supreme Court, if we don't make it here, we will be applying for Supreme Court.' After an avian flu outbreak was detected at the farm last December, the Canadian Food Inspection Agency (CFIA) ordered the farm to cull its remaining herd of approximately 400 birds by Feb. 1, under its 'stamping out' policy, which aims to minimize risk to human health. The agency says the farm has not complied with the Health of Animals Act by failing to report the initial cases of illness and deaths to the CFIA, failing to adhere to quarantine orders and failing to undertake risk mitigation measures. In a statement on its website in May, the CFIA says, 'Given that the flock has had multiple laboratory-confirmed cases of H5N1 and the ongoing serious risks for animal and human health and trade, the CFIA continues planning for humane depopulation with veterinary oversight at the infected premises.' The farm owners argue the remainder of their herd is healthy and have fought for additional and independent testing. According to a website dedicated to saving the ostriches, Karen Espersen and Dave Bilinski, who have owned and worked on the farm for more than 30 years, stopped producing meat at the farm in 2020 and have shifted their focus to research. 'Science is meant to evolve. Policy is meant to evolve, and that's all we're asking is that the Canadian Food Inspection Agency gives us an offer or an option to research these animals more and prove to the Canadians that they are healthy,' Pasitney said. Asked by CTV News why the farm does not trust the expertise of the CFIA, Pasitney says, 'We have experts as well and we have scientific experts, a large panel of them that have really great qualifications.' Following the order to cull the herd, the farm applied for an exemption for animals with rare genetics because of the antibody research they conduct, but the CFIA denied that application on Jan. 10. The farm then applied to the Federal Court for a judicial review of the CFIA's order, but in May, the judge ruled in favour of the CFIA, saying the cull was reasonable and procedurally fair. The Federal Court of Appeal later denied the farm's request for independent testing on June 20 and ordered Tuesday's expedited appeal. The hearing is scheduled for one day. In a statement to CTV News, the CFIA says the agency 'looks forward to a resolution that allows for the continued implementation of its regulatory response, which aims to protect public and animal health, and minimize impacts on the domestic poultry industry and the Canadian economy.' With files from The Canadian Press
